@article{ref1,
title="Drug-risk communication to pharmacists: assessing the impact of risk-minimization strategies on the practice of pharmacy",
journal="Journal of the American Pharmacists Association JAPhA (2003)",
year="2008",
author="Lee, Lauren Y. and Kortepeter, Cindy M. and Willy, Mary E. and Nourjah, Parivash",
volume="48",
number="4",
pages="494-500",
abstract="OBJECTIVES: To gain insight on the knowledge, opinions, barriers, and practices of pharmacists regarding drug risk-minimization tools. DESIGN: Descriptive, nonexperimental, cross-sectional survey. SETTING: 20 states in the United States, fall 2004. PARTICIPANTS: 2,052 randomly selected licensed pharmacists employed in a position requiring an active pharmacist license at the time of the survey and who responded to the survey. INTERVENTION: Participants completed a four-page survey regarding their experience with different types of risk-minimization tools. MAIN OUTCOME MEASURE: Univariate distributions for each question were analyzed. RESULTS: 50% of survey recipients responded to the mailing; 88% of respondents had an active pharmacist license. Of respondents, 18% reported never having received a Dear Healthcare Professional letter and 29% stated that they were not familiar with Medication Guides. Patient package inserts were thought to be somewhat effective by 53% of respondents. Of pharmacists who dispensed a drug with programs for special stickers to be affixed on prescriptions to indicate that the labeled risk had been addressed by the prescriber, 41% reported receiving a prescription without a sticker; 45% dispensed the prescription when stickers were missing. Sixty percent of pharmacists stated that risk-minimization programs have a negative impact on the daily practice of pharmacy; nevertheless, many acknowledged that it was a necessary duty. CONCLUSION: Pharmacists might benefit from additional training on risk-minimization strategies. The successful implementation and impact of risk-minimization programs on the practice of pharmacy should be carefully considered by drug manufacturers and regulators.<p /> <p>Language: en</p>",
language="en",
issn="1544-3191",
doi="10.1331/JAPhA.2008.07045",
url="http://dx.doi.org/10.1331/JAPhA.2008.07045"
}